# CLSP-1025 in p53 R175H solid tumors

Source: https://onco.cc/trials/nct06778863/  
OnCo record `nct06778863` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study tests CLSP-1025, which aims to bring immune cells to cancer cells displaying a particular mutated p53 fragment. Both the mutation and a matching immune-system marker are required.

## Summary

This early study tests CLSP-1025, which aims to bring immune cells to cancer cells displaying a particular mutated p53 fragment. Both the mutation and a matching immune-system marker are required.

Interventional study registered as NCT06778863, sponsored by Clasp Therapeutics, Inc.. Registry phase: 1. Registry enrollment is 90 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT06778863
- Phase: 1
- Setting: Advanced solid tumors with p53 R175H and HLA-A*02:01
- Sponsor: Clasp Therapeutics, Inc.

## Sources

- ClinicalTrials.gov NCT06778863: https://clinicaltrials.gov/study/NCT06778863
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT06778863

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct06778863.json